



LKT Laboratories, Inc.

Romidepsin

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID R5749

CAS No. 128517-07-7

Chemical Name

Synonym FK228, Istodax, Depsipeptide, FR901228, NSC630176

Formula $C_{24}H_{36}N_4O_6S_2$

Formula Wt. 540.70

Melting Point

Purity $\geq 98\%$


Solubility DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description

Romidepsin is a depsipeptide prodrug that inhibits histone deacetylases (HDACs). Romidepsin is currently in clinical trials as a potential treatment for T-cell lymphomas; it displays anticancer chemotherapeutic and antiviral activities. Romidepsin enhances in vitro and in vivo natural killer (NK) cell cytotoxicity by increasing MIC A/B (NK ligand) expression on tumor cells in leukemia and lymphoma models. Romidepsin also induces G0/G1 phase cell cycle arrest and apoptosis, upregulates expression of p21 and p53, downregulates expression of MMP2 and MMP9, and inhibits cell proliferation in non-small cell lung cancer (NSCLC) cells. In vitro, this product also induces HIV expression from infected CD4+ T cells, decreasing persistent latent HIV reservoirs.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
R5749	1 mg	\$371.70
R5749	5 mg	\$1595.50

References Foss F, Coiffier B, Horwitz S, et al. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. *Biomark Res.* 2014 Sep 8;2:16. PMID: 25279222.

Satwani P, Bavishi S, Saha A, et al. Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity. *Cytotherapy.* 2014 May 20. [Epub ahead of print]. PMID: 24856896.

Wei DG, Chiang V, Fyne E, et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. *PLoS Pathog.* 2014 Apr 10;10(4):e1004071. PMID: 24722454.

Karthik S, Sankar R, Varunkumar K, et al. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells. *Biomed Pharmacother.* 2014 Apr;68(3):327-34. PMID: 24485799.

Ueda H, Nakajima H, Hori Y, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by *Chromobacterium violaceum* No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. *J Antibiot (Tokyo).* 1994 Mar;47(3):301-10. PMID: 7513682.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.